Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Employee Rating

0More
TypePublic
HQCrestwood, US
Founded2008
Size (employees)32 (est)
Websiteapellis.com
Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Apellis Pharmaceuticals

Cedric Francois

Cedric Francois

President and CEO
Mike Yeadon

Mike Yeadon

Chief Scientific Officer
Pascal Deschatelets

Pascal Deschatelets

Founder & Chief Operating Officer
Show more

Apellis Pharmaceuticals Office Locations

Apellis Pharmaceuticals has offices in Crestwood, Waltham, Cambridge and San Francisco
Crestwood, US (HQ)
6400 Westwind Way
Cambridge, US
1218 Massachusetts Ave
San Francisco, US
300 41 Grant Ave
Waltham, US
200 5th Ave
Show all (4)
Report incorrect company information

Apellis Pharmaceuticals Financials and Metrics

Apellis Pharmaceuticals Revenue

USD

EBIT (Q2, 2018)

(33.5m)

Market capitalization (14-Dec-2018)

1.1b

Closing stock price (14-Dec-2018)

18.7

Cash (30-Jun-2018)

253.8m
Apellis Pharmaceuticals's current market capitalization is $1.1 b.
Annual
USDFY, 2017

Cash

175.6m

Current Assets

182.0m

Total Assets

182.1m

Accounts Payable

3.7m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018

Cash

13.1m152.9m253.8m

Current Assets

19.0m163.1m266.7m

Total Assets

19.1m163.2m266.8m

Accounts Payable

4.0m4.6m5.1m
Annual
USDFY, 2017

Net Income

(51.0m)

Accounts Payable

932.3k

Cash From Operating Activities

(46.6m)

Cash From Financing Activities

197.4m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018

Net Income

(32.8m)(21.7m)(55.1m)

Accounts Payable

1.5m921.8k1.5m

Cash From Operating Activities

(31.1m)(22.9m)(53.6m)

Cash From Financing Activities

19.3m222.7k131.8m
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Apellis Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Apellis Pharmaceuticals News and Updates

Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH

-  New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA)

Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH

CRESTWOOD, Ky., and WALTHAM, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced i…

Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results

- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) -

Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting

CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today th…

Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy

PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™

Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results

- Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18 -
Show more
Report incorrect company information

Apellis Pharmaceuticals Company Life and Culture

Report incorrect company information

Apellis Pharmaceuticals Frequently Asked Questions

  • When was Apellis Pharmaceuticals founded?

    Apellis Pharmaceuticals was founded in 2008.

  • Who are Apellis Pharmaceuticals key executives?

    Apellis Pharmaceuticals's key executives are Cedric Francois, Mike Yeadon and Pascal Deschatelets.

  • How many employees does Apellis Pharmaceuticals have?

    Apellis Pharmaceuticals has 32 employees.

  • Who are Apellis Pharmaceuticals competitors?

    Competitors of Apellis Pharmaceuticals include MyoKardia, Athersys and Ironwood Pharmaceuticals.

  • Where is Apellis Pharmaceuticals headquarters?

    Apellis Pharmaceuticals headquarters is located at 6400 Westwind Way, Crestwood.

  • Where are Apellis Pharmaceuticals offices?

    Apellis Pharmaceuticals has offices in Crestwood, Waltham, Cambridge and San Francisco.

  • How many offices does Apellis Pharmaceuticals have?

    Apellis Pharmaceuticals has 4 offices.